Acquisition by Encrantz Staffan of 17366 shares of Sight Sciences subject to Rule 16b-3
| SGHT Stock | USD 3.41 0.21 5.80% |
Slightly above 61% of Sight Sciences' investor base is looking to short. The analysis of overall sentiment of trading Sight Sciences stock suggests that many investors are alarmed at this time. Sight Sciences' investing sentiment can be driven by a variety of factors including economic data, Sight Sciences' earnings reports, geopolitical events, and overall market trends.
Sight |
Filed transaction by Sight Sciences Director. Grant, award or other acquisition pursuant to Rule 16b-3
Read at macroaxis.com
Sight Sciences Fundamental Analysis
We analyze Sight Sciences' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sight Sciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sight Sciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Book Value Per Share
Book Value Per Share Comparative Analysis
Sight Sciences is currently under evaluation in book value per share category among its peers. Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
Sight Sciences Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sight Sciences stock to make a market-neutral strategy. Peer analysis of Sight Sciences could also be used in its relative valuation, which is a method of valuing Sight Sciences by comparing valuation metrics with similar companies.
Peers
Sight Sciences Related Equities
| NPCE | Neuropace | 4.70 | ||||
| AVNS | Avanos Medical | 2.22 | ||||
| ANIK | Anika Therapeutics | 1.81 | ||||
| CNMD | CONMED | 0.98 | ||||
| VREX | Varex Imaging | 0.77 | ||||
| AORT | Artivion | 0.65 | ||||
| KIDS | Orthopediatrics Corp | 0.58 | ||||
| TCMD | Tactile Systems | 1.45 | ||||
| CVRX | CVRx | 2.01 | ||||
| OFIX | Orthofix Medical | 2.23 | ||||
| LUNG | Pulmonx Corp | 2.79 | ||||
| FNA | Paragon 28 | 3.09 | ||||
| SIBN | Si Bone | 3.62 |
Additional Tools for Sight Stock Analysis
When running Sight Sciences' price analysis, check to measure Sight Sciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sight Sciences is operating at the current time. Most of Sight Sciences' value examination focuses on studying past and present price action to predict the probability of Sight Sciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sight Sciences' price. Additionally, you may evaluate how the addition of Sight Sciences to your portfolios can decrease your overall portfolio volatility.